Skip to main content

Ebopiprant (C09-1130-631)

Aladdin

Catalog No.
C09-1130-631
Manufacturer No.
E647754-10mg
Manufacturer Name
Aladdin Scientific
Quantity
1
Unit of Measure
EA
Price: $961.08
List Price: $1,067.87

Ebopiprant (OBE022) is an oral and selective prostaglandin F 2α ( PGF 2α ) receptor antagonist, with K i s of 1 nM, 26 nM for human and rat FP receptors, respectively.In VitroEbopiprant (OBE022) and OBE002 are assayed for FP binding affinity by

Enjoy exclusive benefits including discounted pricing on orders by contacting our Sales Executives to open an account.

Adding to cart… The item has been added
Ebopiprant (OBE022) is an oral and selective prostaglandin F 2α ( PGF 2α ) receptor antagonist, with K i s of 1 nM, 26 nM for human and rat FP receptors, respectively.In VitroEbopiprant (OBE022) and OBE002 are assayed for FP binding affinity by competitive binding analysis with 3H-PGF2α using HEK293 cells stably transfected with the FP receptor. Binding affinities (K i ) of OBE022 for the human and rat FP receptor are 1 nM and 26 nM respectively. For OBE002, K i s are 6 nM for the human and 313 nM for the rat FP receptor. The binding of both OBE022 and OBE002 is reversible and competitive since increasing concentrations of either compound causes successive decreases in the slope of the binding curves, consistent with an increase in equilibrium dissociation constant (K D ) without a reduction in receptor density. MCE has not independently confirmed the accuracy of these methods. They are for reference only.In VivoTime-course of the cumulative percentage of delivers mice after RU486-induced preterm parturition at GD17, in OBE022, nifedipine or vehicle treatment groups. Oral treatment with OBE022 delays the preterm birth caused by RU486 administration as reflected by a shift to the right of the percentage of delivery curve. The effect of oral treatment with nifedipine is comparable. Both OBE022 and nifedipine show a trend to increase the time of first pup delivery. As an important consequence of the prolongation of gestation, dams deliver viable pups. Combination of OBE022 and nifedipine cause a synergistic effect on the delay of RU486-induced preterm birth as reflected by a more pronounced shift to the right of the percentage of delivery curve, in comparison to OBE022 or nifedipine alone. Also, a larger increase of the time of first pup delivery is observed . MCE has not independently confirmed the accuracy of these methods. They are for reference only.Form:SolidIC50& Target:Human FP Receptor 1 nM (Ki) Rat FP Receptor 26 nM (Ki). Specification: 0.98 Molecular Formula: C30H34FN3O5S2 Molecular Weight: 599.74 PubChem CID: 122522051 Isomeric SMILES: CC(C)[C@@H](C(=O)OCC[C@@H](C1=CC=C(C=C1)F)NC(=O)[C@H]2N(CCS2)S(=O)(=O)C3=CC=C(C=C3)C4=CC=CC=C4)N
UPC:
12352005
Condition:
New
Availability:
8-12 weeks
Weight:
1.06 Ounces
HazmatClass:
No
WeightUOM:
LB
MPN:
E647754-10mg
CAS:
2005486-31-5
Product Size:
10mg


Cenmed Satisfaction Guarantee

At Cenmed, your confidence and satisfaction are paramount. We guarantee the quality and reliability of our extensive range of clinical and laboratory supplies. If you're not completely satisfied with your purchase, we offer a straightforward return process and dedicated support to resolve your concerns promptly. Our commitment ensures that you can order with confidence, knowing that Cenmed is dedicated to superior service and customer satisfaction. Trust us to meet your needs with every order, backed by our promise of excellence. Learn more in Help & FAQs.


"Cenmed provides me access to the same products/services normally reserved for much larger labs than mine. I was presently surprised by their product offering."

LAB DIRECTOR


"We utilized Cenmed's capabilities for a variety of projects around the world. They are a valued partner and supplier."

PHARMACEUTICAL SUPPLY CHAIN LEADER


"The reps are very good at finding products for customers in this period of supply chain issues."

SCOTT BEHMAN


"Your customer service has been excellent and makes me excited about purchasing with Cenmed in the future!!"

PROCUREMENT + BILLING COORDINATOR AT PHARMA.